tradingkey.logo

OncoCyte Corp <OCX.OQ> expected to post a loss of 24 cents a share - Earnings Preview

ReutersMay 10, 2025 12:38 AM
  • OncoCyte Corp OCX.OQ OCX.O is expected to show a fall in quarterly revenue when it reports results on May 12 for the period ending March 31 2025

  • The Irvine California-based company is expected to report a 28.0% decrease in revenue to $126.75 thousand from $176 thousand a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for OncoCyte Corp is for a loss of 24 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for OncoCyte Corp is $4.50​, above​ its last closing price of $2.87. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.44

-0.43

-1.93

Missed

-351.6

Sep. 30 2024

-0.44

-0.44

-0.98

Missed

-124.8

Jun. 30 2024

-0.55

-0.56

-0.36

Beat

35.6​

Mar. 31 2024

-0.65

-0.67

-1.13

Missed

-69.1

​​Dec. 31 2023

-1.14

-2.12

Missed

-86.5

Sep. 30 2023

-1.00

-1.01

-0.81

Beat

19.6​

Jun. 30 2023

-0.68

-1.30

-1.07

Beat

17.7

Mar. 31 2023

-1.31

-1.84

0.40

Beat

121.7

This summary was machine generated May 10 at 00:38 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles